Entrada Therapeutics (TRDA) Tax Provisions (2023 - 2026)

Entrada Therapeutics' Tax Provisions history runs 4 years deep, the most recent figure standing at $38000.0 for Q1 2026.

• On a quarterly basis, Tax Provisions changed N/A year-over-year to $38000.0 in Q1 2026; TTM through Mar 2026 was $992000.0, a 206.67% increase from a year earlier, with the FY2025 full-year figure at $900000.0, up 4.77% from the prior year.
• Tax Provisions eased to $38000.0 in Q1 2026 per TRDA's latest filing, from $100000.0 in the prior quarter.
• Across five years, Tax Provisions topped out at $18.7 million in Q4 2023 and bottomed at -$17.4 million in Q3 2023.
• The 4-year median for Tax Provisions is $427000.0 (2025), against an average of $1.7 million.
• Across the five-year window, Tax Provisions slumped 110.0% in 2024 and surged 135.16% in 2025, its largest moves.
• Year by year, Tax Provisions stood at $18.7 million in 2023, then slumped by 110.0% to -$1.9 million in 2024, then jumped by 105.35% to $100000.0 in 2025, then tumbled by 62.0% to $38000.0 in 2026.
• Per Business Quant, the three latest TRDA Tax Provisions figures stand at $38000.0 (Q1 2026), $100000.0 (Q4 2025), and $654000.0 (Q3 2025).